| Dr John Larkin Musgrove Jr, MD | |
|
Duke Division Of Nephrology Suite 605 2424 Erwin Road, Durham, NC 27710-0001 | |
| (919) 660-6860 | |
| Not Available |
| Full Name | Dr John Larkin Musgrove Jr |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 10 Years |
| Location | Duke Division Of Nephrology Suite 605 2424 Erwin Road, Durham, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215355524 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 202101825 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Vance County Dialysis | Henderson, NC | Dialysis facility |
| Kerr Lake Dialysis | Henderson, NC | Dialysis facility |
| Duke Health Raleigh Hospital | Raleigh, NC | Hospital |
| Duke University Hospital | Durham, NC | Hospital |
| Duke Regional Hospital | Durham, NC | Hospital |
| Maria Parham Medical Center | Henderson, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Duke Health Integrated Practice Inc | 8325412737 | 2551 |
News Archive
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental biologics license application (sBLA) for licensure of its Influenza A (H1N1) 2009 Monovalent Vaccine.
A team of researchers from the University of Manitoba in collaboration with local clinical scientists in Winnipeg, Canada, have developed a new method for rapid neutrophil chemotaxis test directly from a small drop of whole blood using a microfluidic system.
Halozyme Therapeutics, Inc. today announced the completion of its root cause investigation regarding HYLENEX manufacturing and has identified a corrective action plan and regulatory strategy to reintroduce HYLENEX to the market. Halozyme and Baxter are finalizing the materials for a meeting with the U.S. Food and Drug Administration to seek concurrence with the reintroduction strategy.
TYRX, Inc. announced today that it has successfully implanted its AIGISRx device in 10,000 patients in the United States. The AIGISRx device is an antibacterial mesh technology that securely holds a pacemaker or implantable cardioverter defibrillator in place to create a stable environment, while delivering antimicrobial agents, rifampin and minocycline. These antimicrobial agents have been shown to reduce infections associated with medical devices in multiple randomized controlled trials.
› Verified 1 days ago
| Entity Name | Private Diagnostic Clinic Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457389033 PECOS PAC ID: 1355254368 Enrollment ID: O20031204000577 |
News Archive
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental biologics license application (sBLA) for licensure of its Influenza A (H1N1) 2009 Monovalent Vaccine.
A team of researchers from the University of Manitoba in collaboration with local clinical scientists in Winnipeg, Canada, have developed a new method for rapid neutrophil chemotaxis test directly from a small drop of whole blood using a microfluidic system.
Halozyme Therapeutics, Inc. today announced the completion of its root cause investigation regarding HYLENEX manufacturing and has identified a corrective action plan and regulatory strategy to reintroduce HYLENEX to the market. Halozyme and Baxter are finalizing the materials for a meeting with the U.S. Food and Drug Administration to seek concurrence with the reintroduction strategy.
TYRX, Inc. announced today that it has successfully implanted its AIGISRx device in 10,000 patients in the United States. The AIGISRx device is an antibacterial mesh technology that securely holds a pacemaker or implantable cardioverter defibrillator in place to create a stable environment, while delivering antimicrobial agents, rifampin and minocycline. These antimicrobial agents have been shown to reduce infections associated with medical devices in multiple randomized controlled trials.
› Verified 1 days ago
| Entity Name | Duke Health Integrated Practice Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205553369 PECOS PAC ID: 8325412737 Enrollment ID: O20230327002247 |
News Archive
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental biologics license application (sBLA) for licensure of its Influenza A (H1N1) 2009 Monovalent Vaccine.
A team of researchers from the University of Manitoba in collaboration with local clinical scientists in Winnipeg, Canada, have developed a new method for rapid neutrophil chemotaxis test directly from a small drop of whole blood using a microfluidic system.
Halozyme Therapeutics, Inc. today announced the completion of its root cause investigation regarding HYLENEX manufacturing and has identified a corrective action plan and regulatory strategy to reintroduce HYLENEX to the market. Halozyme and Baxter are finalizing the materials for a meeting with the U.S. Food and Drug Administration to seek concurrence with the reintroduction strategy.
TYRX, Inc. announced today that it has successfully implanted its AIGISRx device in 10,000 patients in the United States. The AIGISRx device is an antibacterial mesh technology that securely holds a pacemaker or implantable cardioverter defibrillator in place to create a stable environment, while delivering antimicrobial agents, rifampin and minocycline. These antimicrobial agents have been shown to reduce infections associated with medical devices in multiple randomized controlled trials.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John Larkin Musgrove Jr, MD 2301 Erwin Rd, Durham, NC 27710 Ph: (919) 684-8111 | Dr John Larkin Musgrove Jr, MD Duke Division Of Nephrology Suite 605 2424 Erwin Road, Durham, NC 27710-0001 Ph: (919) 660-6860 |
News Archive
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental biologics license application (sBLA) for licensure of its Influenza A (H1N1) 2009 Monovalent Vaccine.
A team of researchers from the University of Manitoba in collaboration with local clinical scientists in Winnipeg, Canada, have developed a new method for rapid neutrophil chemotaxis test directly from a small drop of whole blood using a microfluidic system.
Halozyme Therapeutics, Inc. today announced the completion of its root cause investigation regarding HYLENEX manufacturing and has identified a corrective action plan and regulatory strategy to reintroduce HYLENEX to the market. Halozyme and Baxter are finalizing the materials for a meeting with the U.S. Food and Drug Administration to seek concurrence with the reintroduction strategy.
TYRX, Inc. announced today that it has successfully implanted its AIGISRx device in 10,000 patients in the United States. The AIGISRx device is an antibacterial mesh technology that securely holds a pacemaker or implantable cardioverter defibrillator in place to create a stable environment, while delivering antimicrobial agents, rifampin and minocycline. These antimicrobial agents have been shown to reduce infections associated with medical devices in multiple randomized controlled trials.
› Verified 1 days ago
Dr. Stephen John Greene, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2301 Erwin Rd # Dumc3845, Durham, NC 27705 Phone: 919-684-8111 | |
Dr. Jacob Paul Feigal, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: Duke University Hospital Gme, Box 3951, Durham, NC 27710 Phone: 919-684-8111 | |
Dr. David Keith Bright, MD, PHARM D Nephrology Medicare: Accepting Medicare Assignments Practice Location: 4205 Ben Franklin Blvd, Durham, NC 27704 Phone: 919-477-6900 Fax: 919-477-5081 | |
Yuri Anthony Fesko, MD Nephrology Medicare: Medicare Enrolled Practice Location: 4101 N Roxboro St, Durham, NC 27704 Phone: 919-684-8111 | |
Mary E Klotman, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 40 Duke Medicine Cir, Durham, NC 27710 Phone: 919-684-8111 | |
Jonathan Paul Piccini Sr., M.D., M.H.S. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 40 Duke Medicine Cir, Durham, NC 27710 Phone: 919-684-8111 | |
Dr. Deborah Anne Fisher, M.D. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 508 Fulton St, Durham, NC 27705 Phone: 919-286-6945 |